These findings underscore the complex interplay between MYCN and the MDM2-p53 axis in neuroblastoma and suggest that targeting this interaction may hold promise as a therapeutic strategy, particularly in MYCN-amplified cases. Here, MDM2 is linked to neuroblastoma.